Lineage Cell Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company listed in the United States on NYSE American (NYSE/NASDAQ in the broad sense used by many investors), and its corporate headquarters are in Carlsbad, California, United States. The company focuses on developing “off-the-shelf” allogeneic cell therapies designed to address serious medical conditions with substantial unmet need. Its business model is built around a proprietary cell-engineering platform, AlloSCOPE, plus internal development and manufacturing capabilities that matter in cell therapy because consistency, GMP quality, and scalable production can be as important as the biology itself. ([lineagecell.com](https://lineagecell.com/company/)) From a history standpoint, Lineage is the result of a long corporate and strategic evolution that ultimately narrowed the company’s focus toward regenerative medicine and cell therapy. Over time, the business was reshaped into a more specialized biotechnology platform with a clearer clinical pipeline and a sharper identity for capital markets. That repositioning is important for investors because it reduced the company’s “story risk” and made its value proposition more directly tied to a handful of potentially high-value programs. ([investor.lineagecell.com](https://investor.lineagecell.com/node/20211/pdf?utm_source=openai)) The pipeline is centered on several programs. The lead asset is OpRegen (RG6501), a retinal pigment epithelial cell therapy being developed with Roche and Genentech for dry age-related macular degeneration, particularly geographic atrophy. In neuroregeneration, OPC1 targets spinal cord injury and remains a key reference point for the company’s scientific reputation. Lineage also develops VAC2 in immuno-oncology, ANP1 for auditory neuron-related hearing loss, and PNC1 for vision loss linked to photoreceptor dysfunction. In practical terms, this makes Lineage a diversified cell-therapy developer, but one still highly concentrated on specialized, high-risk, high-reward indications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/876343/000095017025060148/lctx_2025_ars.pdf)) Competitively, Lineage is positioned as a niche cell-therapy specialist rather than a broad-based biotech. Its potential advantage lies in allogeneic, ready-to-use products that may be easier to manufacture, store, and deploy than patient-specific therapies. Its main challenges are typical of clinical-stage biotech: long development timelines, regulatory uncertainty, financing needs, and competition from larger pharmaceutical groups and better-capitalized peers pursuing alternative approaches in ophthalmology, neurology, and immunology. Geographically, the company is primarily U.S.-based, with headquarters in Carlsbad, California, and additional operational links to Israel through manufacturing and R&D activities described in its filings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/876343/000095017025060148/lctx_2025_ars.pdf)) Recent developments suggest an active clinical and operational year. In 2025, management highlighted 36-month clinical data updates for OpRegen, progress on commercial-scale GMP manufacturing, a new chronic-patient study in OPC1, and a collaboration with William Demant Invest around ReSonance/ANP1 for sensorineural hearing loss. The company’s 2025-2026 SEC Form 4 filings also show ongoing insider transaction activity, which can be useful context for investors following management incentives and insider sentiment. ([investor.lineagecell.com](https://investor.lineagecell.com/node/24211/pdf))